OncoImmunity Becomes the First Company to Obtain the CE-IVD Mark for Clinical Use of a Machine-Learning Based Neoantigen Prediction Technology
OncoImmunity has become the first company to obtain a CE-IVD mark for the clinical use of a machine-learning based neoantigen prediction technology. This quality assurance certification represents an important step in raising the standards for the use of neoantigen prediction technologies for the design of personalized cancer vaccines and cell therapies.
The certification means that personalized cancer vaccine and cell therapy companies can now meet their own quality assurance requirements for their clinical development by leveraging OncoImmunity’s proven quality assurance methodology. OncoImmunity’s neoantigen prediction technology, known as the Immuneoprofiler™, allows cancer immunotherapy companies to gain access to a quality assured prediction technology that also has superior performance in predicting the presentation of neoantigens to the tumor cell surface.
Richard Stratford CEO at OncoImmunity said:
“At OncoImmunity we understand intimately the complexity of neoantigen prediction and the need to select neoantigens for personalized cancer immunotherapy to a high clinical standard. We have designed machine-learning solutions to fill some of the gaps in the neoantigen prediction challenge and this certification of the Immuneoprofiler™ will facilitate both cost-saving and time-efficient filing for the accreditation of our partners cancer immunotherapy platforms”
The CE-mark (CE-IVD) indicates that an IVD device complies with the European In Vitro Diagnostics Directive (98/79/EC), and that the device may be legally commercialized and distributed in the EU.
OncoImmunity is a machine-learning company offering a proprietary technology to address the key knowledge gaps in the prediction of bona fide immunogenic neoantigens for personalized cancer immunotherapy. OncoImmunity's software facilitates effective patient selection for cancer immunotherapy and identifies neoantigen targets for truly personalized cancer vaccines & cell therapies in a clinically actionable time-frame.
Trevor Clancy Ph.D.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NY-IFF2.6.2020 22:17:10 CEST | Press release
IFF to Webcast Fireside Chat at Stifel Virtual Cross Sector Insight Conference June 8
CA-DOCTOR-EVIDENCE/DRE2.6.2020 16:02:12 CEST | Press release
Dr Evidence (DRE), an AI-Enabled SaaS Healthcare Insights Company, Taps Industry Experts Joseph A. Boystak as Chairman of the Board and Ameet Nathwani, MD, as Chairman of its Newly Formed Medical Strategy Advisory Board
ELEVĒO2.6.2020 16:02:12 CEST | Press release
ZOOM International to Begin Doing Business As Elevēo
PEGASUS-DEVELOPMENT-AG2.6.2020 15:08:08 CEST | Press release
Pegasus Development AG: Pegasus Present Its New Brand Pegastril - Nuevo
NY-PVH2.6.2020 15:02:18 CEST | Press release
PVH Corp. Announces Leadership Update at Tommy Hilfiger and PVH Europe
RE-VANA-THERAPEUTICS2.6.2020 15:02:18 CEST | Press release
Re-Vana Therapeutics Raises $3.25 Million in Pre-Series A Financing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom